Lallemand Probiotic Gains Sports Nutrition, Active Nutrition Claims in Canada
The claims, “Promotes gastrointestinal health in physically active adults” and “Helps reduce the incidence of cold-like symptoms in adults with exercise-induced stress,” have been approved for Lallemand Health Solutions’ Lactobacillus helveticus Lafti L10 strain for active adults.
Photo © Shutterstock.com/Dirima
Lallemand Health Solutions (Montreal) announced that Health Canada has approved two new health claims for active adults for its Lactobacillus helveticus probiotic strain, Lafti 10. The claims, “Promotes gastrointestinal health in physically active adults” and “Helps reduce the incidence of cold-like symptoms in adults with exercise-induced stress,” are now available for Lafti L10.
According to the company, Lafti L10 is “the first clinically tested probiotic strain demonstrating support for athletes’ immune health.” The company said that Lafti L10’s immune-health benefits are supported by results from four clinical studies, as well as several in vitro and in vivo mechanistic studies. In a 2016 study1 published in Applied Physiology, Nutrition, and Metabolism, Lafti L10 significantly reduced the duration of upper respiratory tract illness in elite athletes by 3.4 days.
The market for probiotics in sports nutrition is on the rise, said Lallemand in a press release. Sports nutrition is an especially promising category for probiotics because, it said, athletes are an ideal model for studying the effects of probiotics on the body’s natural defenses.
Also read:
Are Probiotics Moving Beyond Gut Health?
Canada Approves Gut-Brain Axis Health Claims for Lallemand Probiotic
ProbioKid Strains Safe, Well-Tolerated, Study Confirms
References:
1. Michalickova D et al., “Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial,” Applied Physiology, Nutrition, and Metabolism, vol. 41, no. 7 (July 2016): 782-789
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
